Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.
Severson TM, Zhu Y, Prekovic S, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden M, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A, Wessels L, Corey E, Zwart W, Bergman AM.
Severson TM, et al. Among authors: kim y.
medRxiv [Preprint]. 2023 Feb 24:2023.02.24.23286403. doi: 10.1101/2023.02.24.23286403.
medRxiv. 2023.
PMID: 36865297
Free PMC article.
Preprint.